102 related articles for article (PubMed ID: 18186244)
1. [A case of relapsed small-cell lung cancer successfully treated by administration of amrubicin].
Mori H; Tanaka H
Nihon Kokyuki Gakkai Zasshi; 2007 Dec; 45(12):967-70. PubMed ID: 18186244
[TBL] [Abstract][Full Text] [Related]
2. Long-term amrubicin chemotherapy for small-cell lung cancer.
Higashiguchi M; Suzuki H; Hirashima T; Kobayashi M; Goya S; Okamoto N; Matsuura Y; Tamiya M; Morishita N; Kawase I
Anticancer Res; 2012 Apr; 32(4):1423-7. PubMed ID: 22493380
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcome of amrubicin therapy according to the prior chemotherapy sensitivities of extensive small cell lung cancer.
Mitsuoka S; Kudoh S; Kimura T; Yoshimura N; Tanaka H; Suzumura T; Umekawa K; Nagata M; Ueda T; Hirata K
Osaka City Med J; 2011 Dec; 57(2):59-66. PubMed ID: 22443079
[TBL] [Abstract][Full Text] [Related]
4. Complete response of esophageal small cell carcinoma amrubicin treatment.
Nagasaki E; Yuda M; Tanishima Y; Arakawa Y; Kobayashi K; Sakuyama T; Inoue D; Nishikawa K; Kobayashi M; Omura N; Kobayashi T; Aiba K
J Infect Chemother; 2013 Aug; 19(4):770-5. PubMed ID: 23160626
[TBL] [Abstract][Full Text] [Related]
5. A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer.
Shibayama T; Hotta K; Takigawa N; Tada A; Ueoka H; Harita S; Kiura K; Tabata M; Segawa Y; Nogami N; Kuyama S; Shinkai T; Tanimoto M
Lung Cancer; 2006 Aug; 53(2):189-95. PubMed ID: 16806573
[TBL] [Abstract][Full Text] [Related]
6. [A case of small-cell lung cancer effectively treated by bi-weekly administration of amrubicin].
Kurai J; Igishi T; Suyama H; Kodani M; Fukuoka Y; Miyata M; Touge H; Hasegawa Y; Yasuda K; Hitsuda Y; Shimizu E
Gan To Kagaku Ryoho; 2006 Mar; 33(3):373-5. PubMed ID: 16531722
[TBL] [Abstract][Full Text] [Related]
7. [A case of small cell lung cancer under hemodialysis with chronic renal failure treated with amrubicin while measuring blood concentration of the drug].
Goto N; Shibuya H; Har K; Hisada T
Nihon Kokyuki Gakkai Zasshi; 2007 Apr; 45(4):337-43. PubMed ID: 17491313
[TBL] [Abstract][Full Text] [Related]
8. [Our clinical experiences of amrubicin hydrochloride monotherapy in extensive-disease small cell lung cancer].
Kawakami M; Ohno S; Tsujita A; Hosono T; Kobayashi A; Yamasawa H; Bando M; Sugiyama Y
Gan To Kagaku Ryoho; 2008 Feb; 35(2):273-6. PubMed ID: 18281764
[TBL] [Abstract][Full Text] [Related]
9. [Two cases of severe myelosuppression from amrubicin in previously-treated small cell lung cancer].
Suzuki H; Sasada S; Matsuda Y; Otani Y; Morishita N; Kobayashi M; Okamoto N; Hirashima T; Matsui K; Kawase I
Gan To Kagaku Ryoho; 2008 Mar; 35(3):491-3. PubMed ID: 18347402
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.
Inoue A; Sugawara S; Yamazaki K; Maemondo M; Suzuki T; Gomi K; Takanashi S; Inoue C; Inage M; Yokouchi H; Watanabe H; Tsukamoto T; Saijo Y; Ishimoto O; Hommura F; Nukiwa T
J Clin Oncol; 2008 Nov; 26(33):5401-6. PubMed ID: 18854562
[TBL] [Abstract][Full Text] [Related]
11. Amrubicin for non-small-cell lung cancer and small-cell lung cancer.
Kurata T; Okamoto I; Tamura K; Fukuoka M
Invest New Drugs; 2007 Oct; 25(5):499-504. PubMed ID: 17628745
[TBL] [Abstract][Full Text] [Related]
12. Plasma concentration of amrubicinol in plateau phase in patients treated for 3 days with amrubicin is correlated with hematological toxicities.
Kimura T; Kudoh S; Mitsuoka S; Yoshimura N; Tanaka H; Asai K; Kyoh S; Tochino Y; Umekawa K; Hirata K
Anticancer Drugs; 2009 Jul; 20(6):513-8. PubMed ID: 19352172
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.
Ettinger DS; Jotte R; Lorigan P; Gupta V; Garbo L; Alemany C; Conkling P; Spigel DR; Dudek AZ; Shah C; Salgia R; McNally R; Renschler MF; Oliver JW
J Clin Oncol; 2010 May; 28(15):2598-603. PubMed ID: 20385980
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.
Onoda S; Masuda N; Seto T; Eguchi K; Takiguchi Y; Isobe H; Okamoto H; Ogura T; Yokoyama A; Seki N; Asaka-Amano Y; Harada M; Tagawa A; Kunikane H; Yokoba M; Uematsu K; Kuriyama T; Kuroiwa Y; Watanabe K;
J Clin Oncol; 2006 Dec; 24(34):5448-53. PubMed ID: 17135647
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacologic study of weekly amrubicin in patients with refractory or relapsed lung cancer: Central Japan Lung Study Group (CJLSG) 0601 trial.
Kitagawa C; Saka H; Kajikawa S; Mori K; Oki M; Suzuki R
Cancer Chemother Pharmacol; 2012 May; 69(5):1379-85. PubMed ID: 22237957
[TBL] [Abstract][Full Text] [Related]
16. [Retrospective analysis of amrubicin hydrochloride monotherapy in patients with previously treated small-cell lung cancer].
Nitta T; Yamasaki M; Kajihara T; Mito A; Awaya H; Ikegami Y; Arita K
Gan To Kagaku Ryoho; 2010 Jun; 37(6):1045-9. PubMed ID: 20567105
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of amurubicin for the elderly patients with refractory relapsed small cell lung cancer as third-line chemotherapy.
Asai N; Ohkuni Y; Matsunuma R; Nakashima K; Iwasaki T; Kaneko N
J Cancer Res Ther; 2012; 8(2):266-71. PubMed ID: 22842373
[TBL] [Abstract][Full Text] [Related]
18. Amrubicin monotherapy for elderly patients with previously treated lung cancer.
Nakao M; Oguri T; Suzuki T; Kunii E; Tomita Y; Iwashima Y; Miyazaki M; Maeno K; Sato S; Ueda R
Intern Med; 2010; 49(17):1857-62. PubMed ID: 20823645
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer.
Hirose T; Nakashima M; Shirai T; Kusumoto S; Sugiyama T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M
Lung Cancer; 2011 Sep; 73(3):345-50. PubMed ID: 21277039
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401).
Tanaka H; Hasegawa Y; Fujita Y; Nakamura A; Kikuchi E; Kawai Y; Harada T; Watanabe N; Yokouchi H; Usui K; Saito R; Watanabe H; Masuda T; Fukuhara T; Kudo K; Honda R; Oizimi S; Maemondo M; Inoue A; Morikawa N
Thorac Cancer; 2021 Jul; 12(14):2113-2121. PubMed ID: 34076966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]